These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. [JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor]. Olsson AG Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1471-5. PubMed ID: 19579435 [No Abstract] [Full Text] [Related]
27. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Alagona P Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805 [TBL] [Abstract][Full Text] [Related]
28. Prevention and treatment of atherosclerosis: a practitioner's guide for 2008. Lewis SJ Am J Med; 2009 Jan; 122(1 Suppl):S38-50. PubMed ID: 19110087 [TBL] [Abstract][Full Text] [Related]
29. Reassessing the validity of surrogate markers of drug efficacy in the treatment of coronary artery disease. Colatsky TJ Curr Opin Investig Drugs; 2009 Mar; 10(3):239-44. PubMed ID: 19333881 [TBL] [Abstract][Full Text] [Related]
30. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins? Goumas GS Angiology; 2009; 60(1):93-8. PubMed ID: 19019838 [TBL] [Abstract][Full Text] [Related]
31. Role of statins in aortic valve disease. Rajamannan NM Heart Fail Clin; 2006 Oct; 2(4):395-413. PubMed ID: 17448427 [No Abstract] [Full Text] [Related]
32. [About: pleiotropic effects of statins in atherosclerosis]. Ambrosi P Arch Mal Coeur Vaiss; 2005 Dec; 98(12):1263; author reply 1263-5. PubMed ID: 16435610 [No Abstract] [Full Text] [Related]
33. Exaggerated benefits of rosuvastatin compared with other statins. Qizilbash N Pharmacoepidemiol Drug Saf; 2009 May; 18(5):425-6. PubMed ID: 19382149 [No Abstract] [Full Text] [Related]
34. Candidate mechanisms for regression of coronary atherosclerosis with high-dose statins: insight from intravascular ultrasonography trials. Sipahi I; Tuzcu EM Am J Cardiovasc Drugs; 2008; 8(6):365-71. PubMed ID: 19159123 [TBL] [Abstract][Full Text] [Related]
35. Clinical inquiries. Should we treat elevated cholesterol in elderly patients? Korsen N; Nowicki E; Thering A; Solomos N J Fam Pract; 2002 Aug; 51(8):680. PubMed ID: 12184961 [No Abstract] [Full Text] [Related]
36. Synthetic HDL as a new treatment for atherosclerosis regression: has the time come? Conca P; Franceschini G Nutr Metab Cardiovasc Dis; 2008 May; 18(4):329-35. PubMed ID: 18378129 [TBL] [Abstract][Full Text] [Related]
37. Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era. Lavie CJ; Milani RV J Am Coll Cardiol; 2008 Jan; 51(1):56-8. PubMed ID: 18174037 [No Abstract] [Full Text] [Related]
38. The influence of statin medications on prostate-specific antigen levels. Hamilton RJ; Goldberg KC; Platz EA; Freedland SJ J Natl Cancer Inst; 2008 Nov; 100(21):1511-8. PubMed ID: 18957682 [TBL] [Abstract][Full Text] [Related]
39. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein. Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224 [TBL] [Abstract][Full Text] [Related]
40. Achieving cholesterol goals. Current and future drug therapies. Jones PH Postgrad Med; 2003 Aug; 114(2 Suppl):14-21. PubMed ID: 19667635 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]